VisuXL® is a medical device that is effective in various ocular surface disorders (ocular dryness, changes in the continuity of the corneal and conjunctival surface, environmental stress, exposure to UV and ionizing radiation, prolonged use of videoterminals, etc.). Therefore, the aim of this study is to demonstrate that the clinical benefits and quality of life of the swimmers, exposed for a long time to water added with chlorine, are strongly linked to the unique composition of the long-term VisuXL® medical device.
This is a post-market, monocentric, open-label, randomized study of superiority, with the untreated eye considered as a comparator for the eye treated with VisuXL®, to demonstrate the effectiveness of VisuXL® in professional water-polo athletes exposed to pool water after VisuXL® ocular instillations for 2 months. Considered the category of subjects to study, the study is to be considered a fact-finding pilot study in a particular category of subjects. The study population will be enrolled only after having signed the informed consent; in each enrolled subject, only one eye will be treated with VisuXL®, while the other no, as will be considered the comparator, so the two randomized groups will be divided by treated eyes: * Untreated control eye * Eye treated with VisuXL® Each enrolled subject will be instructed to instill, TID, 1-2 drops of VisuXL® always in the same eye during the entire study, according to the present modality: * Morning * Before training (at least one hour before entering the pool) * After training (maximum one hour after the end of the activity) Subjects will continue to instil 1-2 drops of VisuXL®, TID, always in the same eye, even in days without training (including weekends).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
UO Oculistica, Fondazione Policlinico Universitario A. Gemelli
Roma, Italy
break-up time (BUT)
change over time in tear film break-up time (BUT)
Time frame: measured at week 1, 2, 4 and 8 versus baseline
coloration of the ocular surface
Analysis to evaluate the differences over time between the two groups on coloration of the ocular surface (corneal and conjunctival) with fluorescein
Time frame: measured at week 1, 2, 4 and 8 versus baseline
Schirmer I test at 5 min (ST) (without anesthesia)
Analysis to evaluate the differences over time between the two groups on Schirmer I test at 5 min (ST) (without anesthesia)
Time frame: measured at week 1, 2, 4 and 8 versus baseline
Number of beating of eyelashes per minute
Analysis to evaluate the differences over time between the two groups on number of beating of eyelashes per minute
Time frame: measured at week 1, 2, 4 and 8 versus baseline
Tear osmolarity test
Analysis to evaluate the differences over time between the two groups on tear osmolarity test
Time frame: measured at week 1, 2, 4 and 8 versus baseline
Evaluation of visual acuity
Analysis to evaluate the differences over time between the two groups on evaluation of visual acuity
Time frame: measured at week 1, 2, 4 and 8 versus baseline
Questionnaire scores (OSDI)
Analysis to evaluate the differences over time between the two groups on questionnaire scores (OSDI). The overall Ocular Surface Disease score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: measured at week 1, 2, 4 and 8 versus baseline
Subject satisfaction (10 points on the VAS scale)
Analysis to evaluate the differences over time between the two groups on subject satisfaction. (VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level).
Time frame: measured at week 1, 2, 4 and 8